Browsing Tag

Test Update

Compliance & Safety

Anti-TPO Assay Falsely Elevated Recovery

A reagent bulletin from Roche has informed us that the recovery of the Anti-TPO assay has been falsely elevated for a reagent lot that was in use at Corewell Health Grand Rapids from September 2024 until March, 3, 2025. Based on the product evaluation, and in conjunction with a product and safety risk assessment, the remaining risk of false positive results with the Elecsys Anti-TPO assay is in the acceptable range.

We apologize for the inconvenience. Please reach out with any concerns or questions.

Best,

Dr. Alvarez
Yasel Alvarez, Ph.D.
Clinical Chemistry and Immunology
Corewell Health Reference Laboratory, West Michigan

Test Information

Thyroid Peroxidase Antibody, Blood Level [LAB516]

Clinical Implications

The risk of false positive results with the Elecsys anti-TPO assay is generally acceptable with respect to the given discrepancy.

Resources

Roche Customer Bulletin TP-02316

General Information

Update in Beta CTX-1 (Cross Laps) Testing

Effective January 8, 2025, a new version of Beta CTX-1 (Cross Laps) will be implemented with the discontinuation of the previous version.

The analytical measuring range and reference ranges will be updated with the new version of the test. It is recommended to not directly compare the results between the new and old version of the test. If assistance is needed to aid in trending results between the new and old version of the test, please use the contact us link above or contact the Corewell Health Reference Laboratory West, Immunochemistry Department.

TEST INFORMATION

Discontinue: Beta CTX-1 (Cross Laps) LAB3656, Interface Code 55122
NEW: Beta CTX-1 (Cross Laps) LAB1231780, Interface Code 1231780
Compliance & Safety, Hemostasis/Coagulation

Update: Platelet Aggregation Studies Scheduling

Effective immediately, platelet aggregation testing will require a pathology consult prior to scheduling for testing performed at Corewell Health Reference Laboratory West, Grand Rapids. This consult request must be completed prior to scheduling the patient for testing.

After consultation the testing may be ordered and scheduled.

As a reminder testing is performed for scheduled patients Monday – Thursday from 7:30 am-9:30 am at the 35 Michigan Street Laboratory. Patients should be resting, fasting, non-smoking, and should not be pregnant. Patients should avoid taking any prescription or over the counter medications known to affect platelet function for ten (10) days to two (2) weeks prior to the test. Click for a list of medications with known anti-platelet effects.

Test Information:

 

General Information, Immunochemistry

Update to Breath Tests

Effective December 4, 2024, breath methane will be added to Bacterial Overgrowth, Breath Test (LAB3295) and Lactose Intolerance, Breath Test (LAB3097). As a result, the test will include both breath hydrogen and methane. Methane is being added as a small percentage of patients who have either bacterial overgrowth or lactose intolerance will not produce hydrogen when challenged during the test. These patients are considered methane-producers.
In addition, the collection time point of 150 minutes is being eliminated to align with system-wide standards.
Questions may be directed to the Immunochemistry Laboratory using the Contact Us link above.
Cytology, General Information

Update to PAP-HPV Reflexing Algorithm

The algorithm that reflexes HPV testing off the PAP Test (LAB1230097) when the “HPV Reflex” option is selected during PAP ordering will no longer include pregnancy status as a criterion for reflexing on LSIL patients. Prior to this update, if HPV Reflex was selected, a PAP Diagnosis of LSIL on patients 25 and older would only reflex HPV testing if the patient was non-pregnant. Starting 11/6/2024, if HPV Reflex was selected, a PAP Diagnosis of LSIL on patients 25 and older will reflex HPV testing regardless of pregnancy status. This update aligns with current ASCCP Risk-Based Management Consensus guidelines.